What is obstructive sleep apnea?

Obstructive sleep apnea (OSA) is a condition in which the airway repeatedly collapses or narrows during sleep, briefly stopping or reducing breathing. The interruptions are usually ended by a brief arousal from sleep that the person does not consciously remember. Over a night, this can happen dozens or hundreds of times. The classic features are loud snoring, witnessed pauses in breathing, daytime sleepiness, and waking up feeling unrefreshed.

Why it matters beyond sleep quality. Untreated OSA is associated with high blood pressure, atrial fibrillation, stroke, cognitive problems, and increased cardiovascular risk overall. Treating OSA can improve sleep quality, daytime function, and long-term cardiovascular outcomes.

How it is diagnosed. A sleep study (in-laboratory polysomnography or, increasingly, home sleep apnea testing) measures breathing patterns, oxygen levels, heart rate, and sleep stages. The apnea-hypopnea index (AHI) counts breathing events per hour and is used to define severity.

The traditional therapy options.

Continuous positive airway pressure (CPAP): a machine delivers pressurised air through a mask during sleep, keeping the airway open. CPAP is highly effective when used consistently, but mask comfort and consistent use are the structural challenge.

Mandibular advancement device: a custom oral appliance that holds the lower jaw forward during sleep, keeping the airway open. Effective for mild-moderate OSA and for CPAP-intolerant patients with appropriate dental anatomy.

Surgery: several surgical approaches address specific anatomical contributions. Effectiveness depends on what is causing the airway collapse.

Hypoglossal nerve stimulation: a small implanted device that stimulates the nerve to the tongue during sleep, advancing the tongue and opening the airway. An option for selected moderate-severe OSA patients who cannot tolerate CPAP.

The new pharmacotherapy. Tirzepatide (a GLP-1 plus GIP agonist used for diabetes and weight management) is now approved for OSA in patients with obesity. Weight reduction substantially reduces OSA severity in many patients, and tirzepatide treats both the obesity and the OSA. Follow-on GLP-1 OSA programs are reading out. Upper airway pharmacological programs (medicines that increase muscle tone in the upper airway during sleep) are in late-stage trials, with the proposition of treating OSA without weight reduction or device therapy.

What to expect. With effective therapy, most people with OSA experience meaningful improvement in sleep quality, daytime function, and long-term health. The right approach depends on disease severity, anatomy, contributing factors (especially weight), and patient preference. The expanded therapy options in the past several years mean that more people with OSA have a workable treatment path.